What is Diagonal Therapeutics worth?
$458.5Mlast known valuation
Diagonal Therapeutics last raised $125.0M in its Early Stage VC (Series B) (Jan 2026).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Diagonal Therapeutics
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jan 2026 | Early Stage VC (Series B) | $125.0M | ▮ | ▮ |
| Apr 2024 | Early Stage VC (Series A) | $128.0M | ▮ | ▮ |
How Diagonal Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Diagonal Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Diagonal Therapeutics worth?
- Diagonal Therapeutics's last known valuation is $458.5M.
- How much has Diagonal Therapeutics raised?
- Diagonal Therapeutics has raised $271.3M in total funding across 2 recorded rounds.
- When did Diagonal Therapeutics last raise?
- Diagonal Therapeutics last raised in Jan 2026 (Early Stage VC (Series B)), raising $125.0M.